Docetaxel-related interstitial pneumonitis

Area of Science:

• Pulmonary Medicine
• Oncology
• Pharmacology

Background:

• Docetaxel (Taxotere®) is a chemotherapy agent used for locally advanced or metastatic non-small-cell lung cancer.
• Docetaxel-related interstitial lung disease (ILD) is a known, albeit uncommon, adverse event.
• Previous reports indicate ILD onset typically occurs 10-20 days post-docetaxel administration.

Observation:

• A case of pulmonary toxicity presenting as ILD is reported.
• The patient received a relatively low dose of docetaxel.
• ILD onset was observed within 3 days of docetaxel administration, significantly earlier than previously reported.

Findings:

• The patient experienced rapid-onset interstitial lung disease following docetaxel treatment.
• Despite the rapid onset and low-dose administration, the patient responded favorably to corticosteroid therapy.
• Docetaxel administration was discontinued following the diagnosis of ILD.

Implications:

• This case suggests that docetaxel-induced ILD can manifest much earlier than typically observed.
• Early recognition and prompt steroid treatment may be crucial for managing docetaxel-related pulmonary toxicity.
• Further investigation into risk factors and early detection of ILD in patients receiving docetaxel is warranted.